A potential role for astaxanthin in the treatment of bone diseases (Review)

Mol Med Rep. 2020 Sep;22(3):1695-1701. doi: 10.3892/mmr.2020.11284. Epub 2020 Jun 26.

Abstract

Alterations in molecular signaling impair cellular functions and induce degenerative diseases. Among the factors affecting intracellular signaling pathways, oxidative stress serves an important role. Astaxanthin (3,3'‑dihydroxy‑β, β‑carotene-4,4'‑dione), a pigment found in aquatic organisms, belongs to the xanthophylls family. Astaxanthin exerts a strong antioxidant activity and is widely used in food, cosmetic and pharmaceutical industries. Oxidative stress damages bone homeostasis by producing reactive oxygen species and increasing the production of pro‑resorption cytokines, such as interleukin (IL)‑1, tumor necrosis factor‑α and IL‑6. Therefore, antioxidant molecules can counteract the negative effects of oxidative stress on bone. Accordingly, previous studies have demonstrated that supplementation of astaxanthin in bone contributes to the restoration of bone homeostasis. The present review summarizes the negative effects of oxidative stress in bone and explores the role of astaxanthin in counteracting skeletal injuries consequent to oxidative stress.

Keywords: oxidative stress; reactive oxygen species; bone remodeling; astaxanthin; antioxidant.

Publication types

  • Review

MeSH terms

  • Bone Diseases / drug therapy*
  • Bone Diseases / metabolism
  • Humans
  • Interleukin-1 / metabolism
  • Interleukin-6 / metabolism
  • Oxidative Stress / drug effects*
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / metabolism
  • Xanthophylls / pharmacology
  • Xanthophylls / therapeutic use

Substances

  • IL6 protein, human
  • Interleukin-1
  • Interleukin-6
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • Xanthophylls
  • astaxanthine